Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials.
Microglia is thought to be important in Alzheimer's disease. Therefore, our aim was to investigate the usefulness of the microglial marker chitotriosidase in clinical trials. Chitotriosidase was analyzed in cerebrospinal fluid from Alzheimer's disease patients on acetylcholine esterase inhibitors (AChEI) and in cerebrospinal fluid from multiple sclerosis patients before and after natalizumab treatment. Chitotriosidase activity was extremely stable during treatment with the non-inflammatory drug AChEI. However, the immunomodulatory treatment with natalizumab led to lower chitotriosidase activity. Thus, chitotriosidase may be useful in clinical trials where microglia is targeted or as a safety biomarker in other trials where the brain is a bystander organ.
Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden. bob.olsson@medic.gu.se
Bob
B
Olsson
Clas
C
Malmeström
Hans
H
Basun
Peter
P
Annas
Kina
K
Höglund
Lars
L
Lannfelt
Niels
N
Andreasen
Henrik
H
Zetterberg
Kaj
K
Blennow
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002986:Clinical Trials as Topic; D005260:Female; D006596:Hexosaminidases / Q000134:cerebrospinal fluid*; D006801:Humans; D008297:Male; D017628:Microglia / Q000201:enzymology*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000188:drug therapy; D000069442:Natalizumab
D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D000069442:Natalizumab; D006596:Hexosaminidases; C086400:chitotriosidase